Literature DB >> 24889626

Type I interferon is a therapeutic target for virus-induced lethal vascular damage.

Roberto Baccala1, Megan J Welch2, Rosana Gonzalez-Quintial2, Kevin B Walsh2, John R Teijaro2, Anthony Nguyen2, Cherie T Ng2, Brian M Sullivan2, Alessandro Zarpellon3, Zaverio M Ruggeri3, Juan Carlos de la Torre2, Argyrios N Theofilopoulos2, Michael B A Oldstone1.   

Abstract

The outcome of a viral infection reflects the balance between virus virulence and host susceptibility. The clone 13 (Cl13) variant of lymphocytic choriomeningitis virus--a prototype of Old World arenaviruses closely related to Lassa fever virus--elicits in C57BL/6 and BALB/c mice abundant negative immunoregulatory molecules, associated with T-cell exhaustion, negligible T-cell-mediated injury, and high virus titers that persist. Conversely, here we report that in NZB mice, despite the efficient induction of immunoregulatory molecules and high viremia, Cl13 generated a robust cytotoxic T-cell response, resulting in thrombocytopenia, pulmonary endothelial cell loss, vascular leakage, and death within 6-8 d. These pathogenic events required type I IFN (IFN-I) signaling on nonhematopoietic cells and were completely abrogated by IFN-I receptor blockade. Thus, IFN-I may play a prominent role in hemorrhagic fevers and other acute virus infections associated with severe vascular pathology, and targeting IFN-I or downstream effector molecules may be an effective therapeutic approach.

Entities:  

Keywords:  IFN-alpha; LCMV; immunopathology; lung; platelet loss

Mesh:

Substances:

Year:  2014        PMID: 24889626      PMCID: PMC4066519          DOI: 10.1073/pnas.1408148111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

Review 1.  Lassa fever.

Authors:  J B McCormick; S P Fisher-Hoch
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

2.  Molecular recognition by LARGE is essential for expression of functional dystroglycan.

Authors:  Motoi Kanagawa; Fumiaki Saito; Stefan Kunz; Takako Yoshida-Moriguchi; Rita Barresi; Yvonne M Kobayashi; John Muschler; Jan P Dumanski; Daniel E Michele; Michael B A Oldstone; Kevin P Campbell
Journal:  Cell       Date:  2004-06-25       Impact factor: 41.582

3.  Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones.

Authors:  Jan ter Meulen; Marlis Badusche; Judith Satoguina; Thomas Strecker; Oliver Lenz; Cornelius Loeliger; Mohamed Sakho; Kekoura Koulemou; Lamine Koivogui; Achim Hoerauf
Journal:  Virology       Date:  2004-03-30       Impact factor: 3.616

4.  Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway.

Authors:  M T Puglielli; J L Browning; A W Brewer; R D Schreiber; W J Shieh; J D Altman; M B Oldstone; S R Zaki; R Ahmed
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

5.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

6.  Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus.

Authors:  Andrew M Lee; Justin Cruite; Megan J Welch; Brian Sullivan; Michael B A Oldstone
Journal:  Virology       Date:  2013-05-16       Impact factor: 3.616

7.  Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells.

Authors:  N Sevilla; S Kunz; A Holz; H Lewicki; D Homann; H Yamada; K P Campbell; J C de La Torre; M B Oldstone
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

Review 8.  Innate immune response to arenaviral infection: a focus on the highly pathogenic New World hemorrhagic arenaviruses.

Authors:  Takaaki Koma; Cheng Huang; Olga A Kolokoltsova; Allan R Brasier; Slobodan Paessler
Journal:  J Mol Biol       Date:  2013-09-26       Impact factor: 5.469

9.  Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection.

Authors:  Javier A Carrero; Boris Calderon; Emil R Unanue
Journal:  J Exp Med       Date:  2004-08-09       Impact factor: 14.307

10.  Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence.

Authors:  R Ahmed; A Salmi; L D Butler; J M Chiller; M B Oldstone
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  32 in total

Review 1.  Regulation of antiviral T cell responses by type I interferons.

Authors:  Josh Crouse; Ulrich Kalinke; Annette Oxenius
Journal:  Nat Rev Immunol       Date:  2015-03-20       Impact factor: 53.106

2.  Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection.

Authors:  Cherie T Ng; Brian M Sullivan; John R Teijaro; Andrew M Lee; Megan Welch; Stephanie Rice; Kathleen C F Sheehan; Robert D Schreiber; Michael B A Oldstone
Journal:  Cell Host Microbe       Date:  2015-05-13       Impact factor: 21.023

3.  Lymphocytic choriomeningitis virus Clone 13 infection causes either persistence or acute death dependent on IFN-1, cytotoxic T lymphocytes (CTLs), and host genetics.

Authors:  Michael B A Oldstone; Brian C Ware; Lucy E Horton; Megan J Welch; Roberto Aiolfi; Alessandro Zarpellon; Zaverio M Ruggeri; Brian M Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

4.  Autoimmunity: Interferon α or β: which is the culprit in autoimmune disease?

Authors:  Mary K Crow
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

5.  Identification of a Locus in Mice that Regulates the Collateral Damage and Lethality of Virus Infection.

Authors:  Ichiro Misumi; Kevin D Cook; Joseph E Mitchell; Makayla M Lund; Sarah C Vick; Robert H Lee; Toru Uchimura; Wolfgang Bergmeier; Piotr Mieczkowski; Fernando Pardo-Manuel de Villena; Jenny P Y Ting; Jason K Whitmire
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

6.  S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification.

Authors:  John R Teijaro; Sean Studer; Nora Leaf; William B Kiosses; Nhan Nguyen; Kosuke Matsuki; Hideo Negishi; Tadatsugu Taniguchi; Michael B A Oldstone; Hugh Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

Review 7.  STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?

Authors:  Henrique Lemos; Lei Huang; Tracy McGaha; Andrew L Mellor
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

8.  Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection.

Authors:  Rudragouda Channappanavar; Craig Fett; Matthias Mack; Patrick P Ten Eyck; David K Meyerholz; Stanley Perlman
Journal:  J Immunol       Date:  2017-04-03       Impact factor: 5.422

9.  Effective Treatment of Experimental Lymphocytic Choriomeningitis Virus Infection: Consideration of Favipiravir for Use With Infected Organ Transplant Recipients.

Authors:  Brady T Hickerson; Jonna B Westover; Kie-Hoon Jung; Takashi Komeno; Yousuke Furuta; Brian B Gowen
Journal:  J Infect Dis       Date:  2018-07-13       Impact factor: 5.226

Review 10.  Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes.

Authors:  Cherie T Ng; Juan L Mendoza; K Christopher Garcia; Michael B A Oldstone
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.